Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Albert M, Kim"'
Autor:
Aditi R. Saxena, Stephanie‐An Lyle, Kaivan Khavandi, Ruolun Qiu, Mark Whitlock, William P. Esler, Albert M. Kim
Publikováno v:
Diabetes, Obesity and Metabolism. 25:992-1001
Autor:
Rachel J Roth Flach, Chunyan Su, Eliza Bollinger, Christian Cortes, Andrew W Robertson, Alan C Opsahl, Timothy M Coskran, Kevin P Maresca, Edmund J Keliher, Phillip D Yates, Albert M Kim, Amit S Kalgutkar, Leonard Buckbinder
Publikováno v:
PLoS ONE, Vol 14, Iss 3, p e0214150 (2019)
Myeloperoxidase (MPO) is a highly abundant protein within the neutrophil that is associated with lipoprotein oxidation, and increased plasma MPO levels are correlated with poor prognosis after myocardial infarct. Thus, MPO inhibitors have been develo
Externí odkaz:
https://doaj.org/article/1d4d82c1feff4fad91bb96d03ddfbae9
Autor:
Albert M. Kim, Neeta B. Amin, Arthur Bergman, Roberto A. Calle, Theresa Tuthill, Kou Kou, Sudeepta Aggarwal, Naresh Aggarwal, Collin Crowley, Anthony Rinaldi, Santos Carvajal-Gonzalez, Veena Somayaji, Kendra K. Bence, Jessica Mancuso, Trenton T. Ross, Magalie Boucher, William P. Esler, Robert Dullea, Jeffrey A. Pfefferkorn, Małgorzata Inglot, Greg Tesz
Publikováno v:
Nature Medicine. 27:1836-1848
Alterations in lipid metabolism might contribute to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, no pharmacological agents are currently approved in the United States or the European Union for the treatment of NAFLD. Two pa
Autor:
Aditi R, Saxena, Stephanie-An, Lyle, Kaivan, Khavandi, Ruolun, Qiu, Mark, Whitlock, William P, Esler, Albert M, Kim
Publikováno v:
Diabetes, obesitymetabolism.
To assess the safety, tolerability, and pharmacodynamics (PD) of ketohexokinase inhibitor PF-06835919 in participants with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM).This double-blind, placebo-controlled, parallel-gr
Autor:
Arthur Bergman, Kristin Chidsey, Aditi R. Saxena, Ryan M. Esquejo, Donal Gorman, Albert M. Kim, David A. Griffith, Clare Buckeridge
Publikováno v:
Nature Medicine. 27:1079-1087
Agonism of the glucagon-like peptide-1 receptor (GLP-1R) results in glycemic lowering and body weight loss and is a therapeutic strategy to treat type 2 diabetes (T2D) and obesity. We developed danuglipron (PF-06882961), an oral small-molecule GLP-1R
Autor:
Aditi R, Saxena, Donal N, Gorman, Ryan M, Esquejo, Arthur, Bergman, Kristin, Chidsey, Clare, Buckeridge, David A, Griffith, Albert M, Kim
Publikováno v:
Nature medicine. 27(6)
Agonism of the glucagon-like peptide-1 receptor (GLP-1R) results in glycemic lowering and body weight loss and is a therapeutic strategy to treat type 2 diabetes (T2D) and obesity. We developed danuglipron (PF-06882961), an oral small-molecule GLP-1R
Autor:
Donal Gorman, Clare Buckeridge, Kristin Chidsey, Aditi R. Saxena, Arthur Bergman, Albert M. Kim
Publikováno v:
Diabetes. 69
Background: PF-06882961 is an oral small molecule glucagon-like peptide-1 receptor (GLP-1R) agonist with efficacy in nonclinical models comparable to injectable peptidic GLP-1R agonists. This randomized, double-blind, placebo-controlled, multiple asc
Autor:
Gul eErdemli, Albert M Kim, Haisong eJu, Clayton eSpringer, Robert C Penland, Peter K Hoffmann
Publikováno v:
Frontiers in Pharmacology, Vol 3 (2012)
The human cardiac sodium channel (hNav1.5, encoded by the SCN5A gene) is critical for action potential generation and propagation in the heart. Drug-induced sodium channel inhibition decreases the rate of cardiomyocyte depolarization and consequently
Externí odkaz:
https://doaj.org/article/c01e623d03964809aebb32cadc585076
Autor:
Saswata Talukdar, Yan Weng, Jennifer Q. Dong, Veena Somayaji, Timothy P. Rolph, Jeffrey R. Chabot, Roberto A. Calle, Kathryn E. Gropp, Albert M. Kim
Publikováno v:
Diabetes, Obesity and Metabolism. 19:1762-1772
Aims To assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-05231023, a long-acting FGF21 analogue, in obese, hypertriglyceridemic subjects on atorvastatin with or without type 2 diabetes. Methods Subjects received PF-0523102
Autor:
Stuart J. Pocock, Alexander R. Lyon, Daniel M. Bloomfield, Amany El-Gazayerly, Claudio Gimpelewicz, Faiez Zannad, Piotr Ponikowski, Warren Sherman, Fady I. Malik, Wendy Gattis Stough, Marco Metra, Anna Baczynska, Krishna Prasad, Karsten Bruins Slot, Caroline Boulton, Jose Lopez-Sendon, Pieter A. de Graeff, Maureen Cronin, Ian Laws, Isabelle Richard-Lordereau, Benoit Tyl, Karl Swedberg, Stefan D. Anker, Salim Janmohamed, Gerasimos Filippatos, Martin R. Cowie, Lothar Roessig, Heidi Janssen, Santiago Figueroa Perez, Martin Lefkowitz, Pieter A. Doevendans, Marc A. Pfeffer, Giuseppe M.C. Rosano, Narimon Honarpour, Maria Borentain, Albert M. Kim, Maria Angeles Alonso Garcia, John J.V. McMurray, Dominik Lautsch
Publikováno v:
European Journal of Heart Failure. 19:718-727
Despite the availability of a number of different classes of therapeutic agents with proven efficacy in heart failure, the clinical course of heart failure patients is characterized by a reduction in life expectancy, a progressive decline in health-r